© 2024 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Latest Conference Articles
Icosapent Ethyl Reduces MACE Across Range of Baseline Lp(a): REDUCE-IT Analysis
March 29th 2024
ACC.24: Icosapent ethyl was associated with reduced rate of MACE at all baseline levels of Lp(a) in participants with elevated TG and at high risk for CVD.
Bempedoic Acid Associated with Reduced CV Risk in Statin-Intolerant Individuals Regardless of Ethnicity
March 26th 2024
ACC.24: Data from an analysis of the CLEAR Outcomes trial showed bempedoic acid was well-tolerated and reduced CV events in Hispanic/Latinx and non-Hispanic/Latinx participants.
Steven Nissen, MD, Discusses Historic Bempedoic Acid Labeling for CV Risk Reduction
March 26th 2024
CLEAR Outcomes PI Steven Nissen, MD, links findings from the pivotal trial with labeling updates that make bempedoic acid the only nonstatin agent approved to reduce CV risk.
New Data Shed Light on Disparities in Coronary Artery Calcium Screening
March 25th 2024
ACC.24: Findings showed a disproportionate distribution of CAC screening that favors White, educated, affluent, English-speaking individuals.
Remotely Delivered Lipid Lowering Program Results in Sustained Target LDL-C Levels in High-Risk Population
March 25th 2024
ACC.2024: In a cohort of people at high risk of ASCVD, three-quarters achieved target LDL-C levels at 6 months and 12 months while using a remote algorithm-directed program.
Phase 3 Findings on Neffy for Pediatric Patients with Severe Allergies: A Conversation with Motohiro Ebisawa, MD, PhD
March 4th 2024
Dr Ebisawa details the findings he recently presented at the 2024 AAAAI annual meeting, including adverse events and next steps for the study.
Needle-free Epinephrine Delivery: Perceptions of Physicians, Patients, and Caregivers
February 27th 2024
AAAAI 2024. Needle phobia is just one of the barriers to not just using an epinephrine autoinjector but to carrying one at all, according to 2 sets of surveys findings.
New Data Suggest neffy May be Safe, Effective for Treatment of Urticaria Flares
February 26th 2024
AAAAI 2024. In patients with treatment-resistant chronic spontaneous urticaria, neffy 1 mg and 2 mg resulted in improvement in itch, hives, urticaria, and erythema scores 5 minutes after dosing.
Ethnic Minorities Found More Likely to Require Change in Biologic Therapy for Severe Asthma
February 23rd 2024
New data presented at AAAAI 2024 sheds light on real-world patterns of biologic use in a diverse patient population with severe asthma.
EoE in Children Treated with Dupilumab More Severe at Diagnosis, Study Finds
February 23rd 2024
AAAAI 2024. Dupilumab-treated eosinophilic esophagitis in children was also more often associated with comorbid asthma, according to researchers.